AB0228 Increase in global dna methylation at 3 months of methotrexate use is not associated to response in early ra patients

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 1297
• Main Authors: Gosselt, H.R., de Rotte, M.C., Hazes, J.M., de Jonge, R., Heil, S.G.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2018
• Subjects: Adenosylmethionine; Arthritis; Corticosteroids; CpG islands; Deoxyribonucleic acid; DNA; DNA methylation; Folic acid; Leukocytes (mononuclear); Methotrexate; Patients; Peripheral blood mononuclear cells; Rheumatoid arthritis; S-Adenosylmethionine
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2018-eular.3434

BackgroundMethotrexate (MTX) is a first-line therapy in early Rheumatoid Arthritis (eRA). Still, up to 40% of treated patients do not adequately respond to MTX. MTX interferes with the folate cycle, where it indirectly inhibits the global DNA methylation donor S-adenosylmethionine (SAM). Thus, we hypothesised that global DNA methylation changes during MTX use are associated with treatment response.ObjectivesTo examine whether there is a change in global DNA methylation (Δ%Meth) upon MTX use and if this change is associated to MTX response (ΔDAS28) in eRA patients.MethodsDNA was isolated from whole blood (n=120) and Peripheral Blood Mononuclear Cells (PBMCs, n=83) of eRA patients, before and 3 months after MTX use. Samples were collected from the Treatment in the Rotterdam Early Arthritis Cohort (tREACH), a multicenter, stratified single-blind clinical trial of eRA patients. Selected patients received triple (MTX +SSZ + HCQ) or monotherapy (MTX) combined with corticosteroids. 7 CpG sites within Long-Interspersed Nuclear Elements (LINE-1), a proxy for global DNA methylation, were quantified by Sequenom Epityper. Paired t-tests or Wilcoxon Signed Rank tests were conducted to assess a change in methylation. ΔDAS28 score over 3 months was used as a measure for response. Associations between ΔDAS28 and Δ%Meth were corrected for baseline DAS28 in a linear regression model.ResultsIn leukocytes,%Meth did not significantly change over time. However, in PBMCs%Meth in CpG1 (ΔMeth=2.61%, p=0.008), CpG2 (ΔMeth=0.73%, p=0.039) and CpG11.12 (ΔMeth=0.56%, p=0.016) significantly increased over 3 months of MTX use after Bonferroni correction. Δ%Meth in CpG8.9 was significantly associated to the ΔDAS28 (B=0.29, p=0.039), yet this was no longer significant after Bonferroni correction. Δ%Meth was not significantly associated to ΔDAS28 in any of the other LINE1 CpG sites tested.ConclusionsPBMC global DNA methylation in LINE-1 CpG sites increased upon 3 months of MTX use. However, this change in methylation is not associated to MTX response. Further research is needed to investigate the role of global DNA methylation in these patients.Disclosure of InterestNone declared